Clinical Trials Logo

Muscular Dystrophies clinical trials

View clinical trials related to Muscular Dystrophies.

Filter by:

NCT ID: NCT02295748 Completed - Clinical trials for Duchenne Muscular Dystrophy

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This is an open label, long-term extension study in approximately 24 male DMD subjects consisting of children (ages 4-12, inclusive) and adolescents (ages 13-16, inclusive) who participated in the MP-104-CL-005 PK study.

NCT ID: NCT02286947 Completed - Clinical trials for Muscular Dystrophy, Duchenne

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Start date: November 2014
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

NCT ID: NCT02285673 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy

Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Duchenne muscular dystrophy (DMD) is a genetic disorder caused by an absence of dystrophin and characterized by progressive muscle degeneration. There is no cure for DMD at present but, there are several strategies under-researched for treatment of DMD such as steroid treatment, gene theraphy, exon skipping, stop codon read through and gene repair, cell theraphy and theraphy with drug that help to produce utrophin protein. The aim of this study is investigate the eficacy of human umblical cord mesenchymal stem cells on DMD and understanding if wild type gene can be transfered to the patient.

NCT ID: NCT02255552 Completed - Clinical trials for Duchenne Muscular Dystrophy (DMD)

Study of Eteplirsen in DMD Patients

PROMOVI
Start date: November 17, 2014
Phase: Phase 3
Study type: Interventional

The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).

NCT ID: NCT02251600 Completed - Clinical trials for Duchenne Muscular Dystrophy

A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

Start date: December 2014
Phase: Phase 1
Study type: Interventional

Study to characterize the single-state and steady-state dosing of oral deflazacort in pediatric and adolescents subjects.

NCT ID: NCT02246478 Completed - Clinical trials for Duchenne Muscular Dystrophy

A Study of TAS-205 for Duchenne Muscular Dystrophy

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety and pharmacokinetic of TAS-205 in patients with Duchenne Muscular Dystrophy.

NCT ID: NCT02245711 Withdrawn - Clinical trials for Limb Girdle Muscular Dystrophy

Cell Therapy in Limb Girdle Muscular Dystrophy

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study was to study the effect of stem cell therapy on Limb Girdle Muscular Dystrophy patients.

NCT ID: NCT02241928 Withdrawn - Muscular Dystrophy Clinical Trials

Stem Cell Therapy in Muscular Dystrophy

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.

NCT ID: NCT02241434 Withdrawn - Clinical trials for Duchenne Muscular Dystrophy

Stem Cell Therapy in Duchenne Muscular Dystrophy

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.

NCT ID: NCT02239224 Completed - Clinical trials for Facioscapulohumeral Muscular Dystrophy (FSHD)

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Start date: September 4, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies